Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.
about
Systems biology of cisplatin resistance: past, present and futureComparison of the seleno-transcriptome expression between human non-cancerous mammary epithelial cells and two human breast cancer cell linesMeta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients.A MAP3k1 SNP predicts survival of gastric cancer in a Chinese population.Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.Genetic variations and patient-reported quality of life among patients with lung cancerBMP-4 genetic variants and protein expression are associated with platinum-based chemotherapy response and prognosis in NSCLC.EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance.Functional diversity of the glutathione peroxidase gene family among human populations: implications for genetic predisposition to disease and drug response.Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers.
P2860
Q26863585-76CECA9E-FB28-4E99-82DB-5ADE814F40DBQ33599250-8027BFDE-CE95-4FD4-BDB7-AB3FD6EF93B8Q34325669-3D02B43D-B3DC-46EE-BFE8-457AAFD07236Q34387506-7A50CB1A-33E4-4FC5-9E60-F6631BA7796AQ35100937-5405B432-0205-4B9F-967F-59E4A152B437Q35156135-BCEAA2E1-AE79-4A4C-9966-2D7A240FCDC5Q35675274-8BBE3A23-439C-4983-97DD-0D3B73F5FD7BQ36058264-815B42CD-3A3E-4036-B11D-ACB338007251Q37688183-611F4A23-9740-4759-9795-2CEEC8EBCCB1Q38160089-A405C584-804C-49FB-BBB0-B1B55FD2C786Q38694488-77D2CF63-B6D2-48DA-840A-FFAC5303DF88Q38798223-E02FE6F3-3ED6-4C10-9984-50FAA7368E41Q44297212-11760CFB-60FD-4813-A034-7536346D7325Q52732458-0FF4C7C6-8AA4-49F0-889F-BDEE72E1C5C3
P2860
Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Genetic variations in multiple ...... cer treated with chemotherapy.
@ast
Genetic variations in multiple ...... cer treated with chemotherapy.
@en
type
label
Genetic variations in multiple ...... cer treated with chemotherapy.
@ast
Genetic variations in multiple ...... cer treated with chemotherapy.
@en
prefLabel
Genetic variations in multiple ...... cer treated with chemotherapy.
@ast
Genetic variations in multiple ...... cer treated with chemotherapy.
@en
P2093
P2860
P1476
Genetic variations in multiple ...... cer treated with chemotherapy.
@en
P2093
Cassandra Johnson
Gary A Croghan
Jason A Wampfler
Jeremiah A Aakre
Julian Molina
Liewei Wang
Marie C Aubry
V Shane Pankratz
P2860
P304
P356
10.1158/1078-0432.CCR-10-2877
P407
P577
2011-06-01T00:00:00Z